Akeso, Inc. in 1 story
The narratives 9926.HK currently appears in, with its side and exposure in each.
Bull side
1 story- China Becomes Pharma's Global R&D Engine
9926.HK in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Ivonescimab's clinical performance established Akeso as a globally relevant oncology innovator and licensing partner.
Bear side
0 storiesNo bear-side stories for 9926.HK yet.